August 31, 2013

Statins prevent cataracts and reduce CV events in CAD patients with very low LDL-C



 Statins prevent cataracts

Statins lower the rate of cataract by 20% and the risk of cataract was reduced by 50% when treatment was initiated in younger individuals (in their 40s) and the duration of therapy was longer (e.g. up to 14 years).

Statins lower the rate of cataract by 20%, according to research presented at the ESC Congress today by Professor John B. Kostis from New Jersey, USA. The risk of cataract was reduced by 50% when treatment was initiated in younger individuals (in their 40s) and the duration of therapy was longer (e.g. up to 14 years).

Cataracts are the leading cause of visual impairment worldwide affecting more than 20 million people. Statins are among the most commonly prescribed medications. In the USA they are prescribed to 1 in 3 people over 45 years of age at a cost of $35 billion annually.




Statins reduce CV events in CAD patients with very low LDL-C

Aggressive treatment with statins reduces the risk of subsequent cardiovascular events in patients with coronary artery disease (CAD) even if they have very low LDL cholesterol (LDL-C) levels.

Aggressive treatment with statins reduces the risk of subsequent cardiovascular events in patients with coronary artery disease (CAD) even if they have very low LDL cholesterol (LDL-C) levels, reveals research presented at ESC Congress 2013 today by Dr Emi Nakano from Japan.